TY  - JOUR
A1  - Rao, Martin
A1  - Ippolito, Giuseppe
A1  - Mfinanga, Sayoki
A1  - Ntoumi, Francine
A1  - Yeboah-Manu, Dorothy
A1  - Vilaplana, Cris
A1  - Zumla, Alimuddin
A1  - Maeurer, Markus
T1  - Improving treatment outcomes for MDR-TB — novel host-directed therapies and personalised medicine of the future
T2  - International journal of infectious diseases
N2  - Multidrug-resistant TB (MDR-TB) is a major threat to global health security. In 2017, only 50% of patients with MDR-TB who received WHO-recommended treatment were cured. Most MDR-TB patients who recover continue to suffer from functional disability due to long-term lung damage. Whilst new MDR-TB treatment regimens are becoming available, conventional drug therapies need to be complemented with host-directed therapies (HDTs) to reduce tissue damage and improve functional treatment outcomes. This viewpoint highlights recent data on biomarkers, immune cells, circulating effector molecules and genetics which could be utilised for developing personalised HDTs. Novel technologies currently used for cancer therapy which could facilitate in-depth understanding of host genetics and the microbiome in patients with MDR-TB are discussed. Against this background, personalised cell-based HDTs for adjunct MDR-TB treatment to improve clinical outcomes are proposed as a possibility for complementing standard therapy and other HDT agents. Insights into the molecular biology of the mechanisms of action of cellular HDTs may also aid to devise non-cell-based therapies targeting defined inflammatory pathway(s) in Mtb-driven immunopathology.
KW  - Multidrug-resistant tuberculosis
KW  - Clinical studies
KW  - Host-directed therapies
KW  - Personalised medicine
KW  - Immunotherapy
KW  - Biomarkers
Y1  - 2019
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/50120
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-501203
SN  - 1201-9712
SN  - 1878-3511
N1  - © 2019 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
VL  - 80
IS  - Supplement
SP  - S62
EP  - S67
PB  - Elsevier
CY  - Amsterdam [u. a.]
ER  -